Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6063785 | 0.91 | GAA (0.41) | GAALMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL29012393 | 0.83 | DPP4 (0.39) | GAALMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL29860105 | 0.83 | DPP4 (0.39) | GAALMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL31679541 | 0.83 | DPP4 (0.39) | GAALMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL31357887 | 0.80 | SMN1; SMN2 (0.53) | GAALMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL6062450 | 0.80 | GAA (0.42) | GAALMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL31171230 | 0.78 | GAA (0.41) | GAALMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL3699376 | 0.78 | GAA (0.45) | GAALMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL31171227 | 0.78 | GAA (0.41) | GAALMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL24378718 | 0.77 | SMN1; SMN2 (0.51) | GAALMNAPOLBSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | GAA 1410/4885LMNA 3764/4885POLB 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.